Atrivita ApS: Financial statements 2024
CVR: 42734233
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Atrivita ApS (CVR 42734233) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 389,121 and a net result of DKK 290,857 compared with DKK 468,941 the year before. That is a decrease of 35.9% compared with the year before. Equity in the 2024 report amounted to DKK 859,189. The solvency ratio was 62%.
- Gross Profit
- DKK 389,121
- Profit/Loss
- DKK 290,857
- Equity
- DKK 859,189
- Total Assets
- DKK 1,386,681
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
On September 12, 2024, the company changed its name from MedPro Health ApS to Atrivita ApS.
Atrivita ApS has published its annual report for 2023. Gross profit came to DKK 606,915, and the net result was DKK 468,941.
About Atrivita ApS
Atrivita ApS is a Danish company of the type Anpartsselskab based in Herlev, founded in 2021. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named MedPro Health ApS. The management consists of Bo Tandrup. The board consists of Ivan Berkes (chair). The company is owned by COMMERCE PHARMA HOLDING ApS and London Pharma Capital Limited. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK 1,618,949 and a net result of DKK 635,955 compared with DKK 290,857 the year before. Equity in the 2025 report amounted to DKK 1,495,144.